Genedrive plc (LSE:GDR) has expanded its international footprint with the implementation of its Genedrive® MT-RNR1 ID Kit at the Neonatal Intensive Care Unit of Dublin’s Rotunda Hospital — the company’s first installation outside the UK. Funded by the Rotunda Foundation, the initiative forms part of the Early Identification of Susceptibility to Gentamicin-Induced Hearing Loss programme. The deployment underscores the clinical value of Genedrive’s rapid bedside genetic test, which identifies newborns at risk of gentamicin-related hearing loss, improving patient safety and enhancing neonatal care outcomes. The rollout is supported by the ÉISTIGÍ project and the Charlotte Stoker Fund, reinforcing growing recognition of pharmacogenetic testing as a key advancement in personalized medicine.
Despite ongoing profitability challenges, Genedrive continues to show positive operational progress, supported by revenue growth and a stable balance sheet. While technical indicators suggest bearish short-term momentum and valuations remain constrained by limited earnings, the company’s latest international deployment strengthens its market positioning and long-term outlook.
More about Genedrive plc
Genedrive plc is a UK-based molecular diagnostics company specializing in rapid, affordable point-of-care genetic testing. Its flagship products — the Genedrive® MT-RNR1 ID Kit and the Genedrive® CYP2C19 ID Kit — enable clinicians to make precise, time-critical treatment decisions in neonatal and emergency care. Developed in collaboration with NHS partners and recommended by NICE for use within the UK healthcare system, Genedrive’s technologies are helping to advance the adoption of pharmacogenetic testing worldwide.
Leave a Reply